Pharmaceuticals & Healthcare
Company Size
25,000+ Employees
A Global Pharmaceutical Leader Used Blackbird.AI to Monitor Narrative Risk and Protect Public Trust During a High-Stakes Product Rollout
50%
reduction in analyst hours tied to reputational risk reviews
75%
broader network coverage achieved through Constellation vs. traditional social listening tools
12x
faster identification of narrative attacks using Blackbird.AI’s Constellation Platform
35%
of harmful narratives traced to coordinated amplification targeting product credibility
Problem Statement
As a leading pharmaceutical company prepared to launch a high-profile therapeutic product, it encountered growing narrative pressure across social and media ecosystems. Claims questioning the drug’s safety, approval process, and corporate intent began to surface online, spanning fringe networks, influencer accounts, and emerging media outlets. These harmful narratives posed serious risks to regulatory confidence, prescriber trust, and global market adoption if left unchecked.
Process Before Blackbird.AI
Before using Blackbird.AI, the company relied on standard media monitoring and social listening tools to assess sentiment and coverage volume. While helpful at the surface level, these systems did not expose coordinated threats, identify early-stage amplification patterns, or flag emerging influencers shaping public perception. Communications teams were often reacting to headlines instead of preventing them.
Solution
Blackbird.AI’s Constellation Platform was implemented to deliver real-time visibility into emerging narrative threats. The platform surfaced clusters of false and distorted claims as they developed, identifying which communities and actors were driving amplification. Narrative clusters were mapped across regions and platforms, enabling the company to craft localized responses while maintaining global messaging alignment. Constellation also provided executive-ready risk summaries tied to specific brand exposures.
Customer Impact
With Constellation integrated into the company’s launch workflow, legal, communications, and regulatory teams collaborated around a single source of truth. Early identification of high-risk narratives enabled proactive messaging, reduced regulatory friction, and preserved confidence among patients and prescribers. The company maintained narrative control during a critical market introduction and set a new standard for reputational preparedness in future product launches.